Skip to Content
You are currently on the new version of our website. Access the old version .
MDPIMDPI

Advanced

BiomoleculesBiomolecules
PDF
  • Article
  • Open Access

4 October 2026

11 Pages

Lack of Association Between CAT rs1001179 and SOD2 rs4880 Variants and Risk for Multiple Sclerosis

,
,
,
,
,
,
,
,
…
1
Institute of Molecular Pathology Biomarkers, University of Extremadura, Av/de la Universidad S/N, 10071 Cáceres, Spain
2
CIBERNED (Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas), Instituto de Salud Carlos III, 28029 Madrid, Spain
3
Service of Neurology, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain
4
Section of Neurology, Hospital La Mancha-Centro, Ciudad Real, 13600 Alcázar de San Juan, Spain
Biomolecules2026, 16(10), 1449;https://doi.org/10.3390/biom16101449
This article belongs to the Special Issue Molecular Advances in Multiple Sclerosis
Version Notes
Review Reports
Order Reprints

Abstract

Objectives: Several lines of evidence point to a potential involvement of oxidative stress in the pathophysiology of multiple sclerosis (MS). Superoxide dismutase isoenzymes 1 and 2 (SOD1 and SOD2) and catalase (CAT) are key components of the enzymatic antioxidant defense system. Consequently, genetic variation in the genes encoding these enzymes may influence susceptibility to MS. However, previous studies examining the relationship between SOD1, SOD2, and CAT variants and MS susceptibility have yielded inconsistent findings. The present study aimed to investigate whether two common single-nucleotide variants (SNVs) in CAT and SOD2 are associated with MS risk in a Caucasian Spanish population. Methods: We investigated the CAT rs1001179 and SOD2 rs4880 variants in 300 patients with MS and 400 healthy controls using allele-specific TaqMan quantitative PCR assays. We further examined whether these variants were related to relevant clinical characteristics, including age at disease onset, disease severity, and clinical course/subtype. Results: Neither the genotype nor allele distributions of CAT rs1001179 and SOD2 rs4880 differed significantly between patients with MS and healthy controls. Furthermore, no significant relationships were observed between either variant and sex, age at disease onset, disease severity, or clinical MS subtype. Conclusions: The present study did not detect significant associations between the CAT rs1001179 or SOD2 rs4880 variants and MS susceptibility in the Caucasian Spanish population. Similarly, no significant associations were detected between these variants and the clinical characteristics evaluated. However, smaller genetic effects cannot be excluded.

1. Introduction

Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS) characterized by inflammatory processes, demyelination, and progressive neuronal damage. Genetic susceptibility is an important determinant of MS risk, and genome-wide association studies (GWAS) have identified more than 200 susceptibility loci to date [1,2]. Nevertheless, the effect sizes associated with most of these variants are relatively modest, and collectively they account for only a proportion of the genetic component of MS susceptibility [1,2]. The strongest genetic association has consistently been observed within the HLA region, particularly the HLA-DRB115:01* haplotype [1].
Genetic susceptibility alone, however, is unlikely to fully account for the development and clinical course of MS. Several environmental exposures and interactions between genetic and environmental factors have been proposed as contributors to disease onset and progression. These include reduced sunlight exposure and consequent low vitamin D status, infectious agents—most notably Epstein–Barr virus—along with obesity and cigarette smoking [3,4,5]. Increasing evidence also points to oxidative stress as a relevant component of MS pathophysiology. Because oxidative imbalance is closely interconnected with inflammatory mechanisms [6,7,8], excessive production of reactive oxygen species and impaired antioxidant defenses may contribute to the tissue injury and neurodegenerative processes observed in MS [9,10,11,12].
Superoxide dismutase isoenzymes 1 and 2 (SOD1 and SOD2) and catalase (CAT) are among the principal enzymatic systems involved in the cellular response to oxidative stress. However, studies evaluating SOD and CAT activity in patients with multiple sclerosis (MS) have yielded inconsistent findings [12]. Increased SOD1 and SOD2 enzymatic activity has been reported in actively demyelinating lesions [13], as well as in the cerebellar gray matter of individuals with MS [14]. Reduced SOD activity has been described in erythrocytes [15,16], leukocytes [16], and peripheral blood mononuclear cells (PBMCs) [17] from patients with MS. In serum or plasma, SOD activity has been reported to be either comparable to that of controls [18,19,20], elevated [21,22,23,24], or reduced [25,26]. CAT activity has also shown substantial variability across biological compartments. Increased CAT activity has been detected in active demyelinating lesions [14], whereas erythrocyte CAT activity has been reported to be lower [27] or similar [28] in patients with MS compared with controls. CAT activity in leukocytes was comparable between groups [28], while increased activity has been observed in PBMCs from patients with MS [26]. Similarly, serum/plasma CAT activity has been described as either higher [19,21,24] or unchanged [18,28] in MS patients relative to controls.
Given the established involvement of SOD and CAT in the regulation of oxidative stress, together with the potential contribution of oxidative imbalance to MS pathophysiology, genetic variation in the genes encoding these antioxidant enzymes may hypothetically represent a potential determinant of MS susceptibility. In this context, a study involving 140 patients with MS and 142 controls reported an association between the SOD2 rs4880 and CAT rs7943316 variants and altered susceptibility to MS [29]. In contrast, a more recent study comprising 200 patients with MS and 265 controls found no significant association between MS risk and either SOD2 rs4880 or CAT rs1001179, although both variants were associated with selected motor and sensory manifestations and with the presence of spinal cord lesions [30]. The present study evaluated whether the SOD2 rs4880 and CAT rs1001179 variants are associated with susceptibility to multiple sclerosis (MS) in an independent and larger cohort of Spanish Caucasian patients and healthy controls.

2. Patients and Methods

2.1. Patients and Controls

The study comprised 300 Caucasian Spanish patients with MS who fulfilled the McDonald criteria for definite MS [31] and had no previous diagnosis of other autoimmune or neurological disorders. The control group consisted of 400 healthy, age- and sex-matched individuals who were unrelated to the patients. Controls were eligible provided that none of their first-degree relatives had a history of autoimmune or neurological disease. The demographic and clinical characteristics of both groups are presented in Table 1.
Table 1. Demographic and clinical data of the series studied.
Patients with MS were recruited from several Spanish centers: the Multiple Sclerosis Association of Madrid (N= 165), Hospital La Mancha-Centro (Alcázar de San Juan, Ciudad Real, Spain; N = 65), University Hospital “Doce de Octubre” (Madrid; N = 30), University Hospital “Príncipe de Asturias” (Alcalá de Henares, Madrid; N = 25), and University Hospital del Sureste (Arganda del Rey, Madrid; N = 15). Healthy controls were recruited at the University Hospital of Badajoz (Badajoz, Spain).
Some participants in the present cohort had previously been included in genetic association studies conducted by our group (the previously published papers resulting from these studies have been mentioned in the Supplementary Material). The oldest DNA samples had been stored for approximately 30 years at −80 °C. Before inclusion, DNA quality and genotyping performance were verified, and only samples producing reliable genotype calls were analyzed. There was no overlap between participants included in the present study and those included in previous studies analyzing the CAT rs1001179 and SOD2 rs4880 variants.

2.2. Ethical Aspects

The study was conducted in accordance with the ethical principles established by the Declaration of Helsinki (1975) and received approval from the respective Clinical Research Ethics Committees of the University Hospital “Príncipe de Asturias” (University of Alcalá, Alcalá de Henares, Madrid, Spain; approval code PI02/2005, 27 April 2005) and the University Hospital of Badajoz (Badajoz, Spain no approval code; 1 April 2004). All participants provided written informed consent after receiving detailed information about the study procedures and objectives.

2.3. Genotyping of CAT rs1001179 and SOD2 rs4880 Variants

Genomic DNA was isolated from peripheral blood leukocytes obtained from venous blood samples collected from patients with MS and healthy controls. Genotyping was carried out using real-time PCR on an Applied Biosystems 7500 qPCR system with custom TaqMan assays (Life Technologies, Alcobendas, Madrid, Spain). Two common single-nucleotide variants (SNVs), CAT rs1001179 and SOD2 rs4880 were selected for analysis because both are functionally relevant variants previously investigated in case–control studies of MS [29,30]. Their selection was further supported by evidence linking these variants to other neurodegenerative diseases, whereas comparable evidence for other CAT or SOD2 variants remains limited. CAT rs1001179 is an upstream variant located on chromosome 11, whereas SOD2 rs4880 is a missense variant located on chromosome 6 that results in a valine-to-alanine substitution at amino acid position 16 (Val16Ala) in the SOD2 protein. The corresponding TaqMan assays were C__11468118_10 and C___8709053_10, respectively.
Genotyping quality control included no-template negative controls in each run, which showed no amplification. In addition, 10% of randomly selected samples were genotyped in triplicate, with 100% concordance among determinations. The initial genotype call rates were 95% for CAT rs1001179 and 98% for SOD2 rs4880. Samples with an initially unsuccessful or ambiguous result were re-genotyped, and a definitive genotype was obtained for all 700 participants. Thus, the final call rate was 100% for both variants, and no samples were excluded from the analysis because of genotyping failure.

2.4. Statistical Analysis

Statistical analyses were performed using SPSS Statistics version 27.0 for Windows (SPSS Inc., Chicago, IL, USA). Hardy–Weinberg equilibrium was evaluated independently in the MS and control groups using the online Hardy–Weinberg equilibrium calculator (https://codingace.net/biology/hardy_weinberg.html; accessed on 15 August 2026). Allelic and genotypic distributions were analyzed with PLINK software version 1.9 (beta 7.11) [32]. Differences in genotype and allele distributions between groups were evaluated using the chi-square test or Fisher’s exact test, as appropriate. Analyses were performed for the overall study population and separately after stratification by sex. Analyses stratified by sex, age at onset, Expanded Disability Status Scale (EDSS), and clinical subtype were considered exploratory because the study was not specifically powered to detect associations within these subgroups. For these exploratory subgroup analyses, age at onset and EDSS were dichotomized using their respective median values in the study population, 31 years and 3, to obtain groups of approximately equal size. These data-driven thresholds were not prespecified clinical cutoffs. Odds ratios and their 95% confidence intervals were calculated to estimate the magnitude and precision of the associations. To account for multiple testing, p-values were adjusted using the false discovery rate (FDR) method [33]. FDR correction was performed separately for genotype and allele analyses within each analysis or stratification: all genotype comparisons were included in one correction set, and all allele comparisons were included in a separate correction set. FDR-adjusted p values are reported as Pc. Genotype and allele frequencies were additionally compared among MS patient subgroups defined according to age at disease onset, disease severity as measured by the EDSS, and clinical disease course. The chi-square or Fisher’s exact test was used for these subgroup analyses, as appropriate.
Sample size and statistical power were estimated under a genetic model based on the frequency of the less common allele and an assumed OR of 1.5, with a two-sided α level of 0.05. The minor allele frequencies observed among healthy controls were used for these calculations. Given the sample size of the present study, the estimated statistical power was 90.3% for CAT rs1001179 and 96.2% for SOD2 rs4880.

3. Results

After adjustment for multiple comparisons, neither genotype nor allele distributions for CAT rs1001179 and SOD2 rs4880 differed significantly between patients with MS and controls. The Hardy–Weinberg equilibrium test showed no significant deviation for either polymorphism. For CAT rs1001179, the Hardy–Weinberg p values in patients and controls were p = 0.8222 and p = 0.128, respectively. For SOD2 rs4880, the corresponding p values were p = 0.443 and p = 0.908, respectively. These findings remained unchanged when the analysis was performed in the overall cohort (Table 2) or separately in men and women (Table 3).
Table 2. Genotypes and allelic variants of CAT rs1001179 and SOD2 rs4880 of patients with MS and healthy volunteers. The values in each cell represent: number (percentage; 95% confidence intervals).
Table 3. Genotypes and allelic variants of CAT rs1001179 and SOD2 rs4880 in patients with MS and healthy volunteers stratified by sex. The values in each cell represent: number (percentage; 95% confidence intervals).
When patients with MS were divided according to age at disease onset, using the median age of 31 years as the threshold, the genotype and allele distributions of the two SNVs examined were comparable between patients with an onset at ≥31 years and those with an onset at ≤30 years (Table 4). Likewise, no significant differences in genotype or allele frequencies were observed after stratifying patients according to the median EDSS score of 3, with comparable distributions in those with EDSS < 3 and EDSS ≥ 3 (Table 5).
Table 4. Genotypes and allelic variants of CAT rs1001179 and SOD2 rs4880 in patients with MS according to age at onset. The values in each cell represent: number (percentage; 95% confidence intervals).
Table 5. Genotypes and allelic variants of CAT rs1001179 and SOD2 rs4880 in patients with MS according to EDSS scores. The values in each cell represent: number (percentage; 95% confidence intervals).
We further explored whether age at disease onset was related to disability, as assessed by the EDSS. Linear regression analysis revealed no significant association between these two variables (p = 0.610). Similarly, chronological age was not significantly correlated with EDSS scores (p = 0.624).
Finally, genotype and allele frequencies for CAT rs1001179 and SOD2 rs4880 were broadly comparable across the three clinical courses of MS—relapsing–remitting, secondary progressive, and primary progressive—and the control group (Table 6).
Table 6. Genotypes and allelic variants of CAT rs1001179 and SOD2 rs4880 in patients with MS according to clinical subtype of MS. The values in each cell represent: number (percentage; 95% confidence intervals).

4. Discussion

Although accumulating evidence supports a potential involvement of oxidative stress in MS pathophysiology [9,10,11,12], and altered SOD1, SOD2, and CAT activities have been documented in several tissues [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28], the extent to which genetic variation in SOD1, SOD2, and CAT influences susceptibility to MS remains uncertain. This issue has received limited attention, and the available genetic association studies have yielded inconsistent findings. For example, the SOD2 rs4880 polymorphism was associated with MS susceptibility in one study [29], whereas no significant association was detected in another [30]. Similarly, an association between the CAT rs7943316 variant and MS was reported by one group [29], while a different study found no association between the CAT rs1001179 variant and MS risk [30].
In addition to the studies conducted in MS, the CAT rs1001179 variant has been investigated in several neurodegenerative diseases, including Alzheimer’s disease [34,35], amyotrophic lateral sclerosis [36], and spinal muscular atrophy [37], as well as in the risk of developing motor complications associated with dopaminergic treatment in Parkinson’s disease [38,39]. Similarly, SOD2 rs4880 is a widely investigated functional variant that has been studied in several neurodegenerative diseases, particularly Alzheimer’s disease [40,41,42], amyotrophic lateral sclerosis [36], spinal muscular atrophy [37], Parkinson’s disease [43,44,45], and motor complications of levodopa therapy in patients with Parkinson’s disease [38,39].
In this Spanish cohort, comprising 300 patients with MS and 400 controls, we did not detect a significant association between either the CAT rs1001179 or SOD2 rs4880 variant and susceptibility to MS. This lack of association was observed in the overall study population and remained unchanged when the analyses were performed separately in men and women, in line with the findings previously reported by Siokas et al. [30]. Furthermore, no significant associations were detected between either of the two SNVs and age at disease onset, disability as measured by the EDSS, or the clinical course of MS.
Wigner et al. [29] reported associations of SOD2 and CAT variants with MS risk, whereas Siokas et al. [30] found no association of SOD2 or CAT variants with disease susceptibility, although both variants were associated with selected clinical manifestations and spinal cord lesions. Our susceptibility findings agree with those of Siokas et al. [30] but differ from the association reported for SOD2 rs4880 by Wigner et al. [29]. Differences in population ancestry, sample size, clinical characteristics, and study design may contribute to these discrepancies. Additional CAT variants, including rs769214, rs769217 and rs7943316, warrant investigation in larger, independent cohorts. Future studies should assess a broader set of variants and incorporate prospective clinical follow-up to determine whether antioxidant-related genetic variation influences MS susceptibility or progression.
Several limitations should be considered when interpreting our findings. First, although the sample size provided adequate statistical power to detect effects of OR ≥ 1.5, the study had less power to identify smaller effects. Second, heterogeneity in disease severity may have reduced our ability to identify associations between the investigated variants and MS-related disability. Third, the analysis was restricted to two SNVs, one in each of the CAT and SOD2 genes, and therefore does not exclude a contribution from other variants in these genes. Finally, the subgroup analyses were exploratory and had limited statistical power, particularly for smaller subgroups such as patients with primary progressive MS. Dichotomization of age at onset and EDSS may also have resulted in loss of information and statistical power. Therefore, the absence of statistically significant findings, particularly in the subgroup analyses, should not be interpreted as definitive evidence that smaller associations are absent.
Future research would benefit from larger prospective studies enrolling individuals shortly after MS diagnosis, with systematic genotyping and prolonged clinical follow-up. Such studies could clarify whether antioxidant-related genetic variants influence subsequent disease progression or clinical phenotype.

5. Conclusions

The present study did not detect significant associations between the CAT rs1001179 or SOD2 rs4880 variants and susceptibility to multiple sclerosis in the Spanish Caucasian population studied. Similarly, no significant associations were detected between these variants and sex, age at disease onset, disability, or clinical course. However, smaller genetic effects cannot be excluded, and the subgroup analyses should be considered exploratory. Further studies involving larger independent cohorts and a broader range of genetic variants are warranted.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biom16101449/s1, The references of previous genetic association studies by our group that included some of the same participants, but analyzed different variants/hypotheses.

Author Contributions

Conceptualization, E.G.-M., J.A.G.A., H.A.-N. and F.J.J.-J.; Data curation, E.G.-M., J.G.-T., J.A.G.A., J.B.-L., J.M.-P., M.D.-S., P.C., L.T.-F., H.A.-N., E.G.-A. and F.J.J.-J.; Formal analysis, E.G.-M., J.A.G.A., H.A.-N. and F.J.J.-J.; Funding acquisition, E.G.-M. and J.A.G.A.; Investigation, E.G.-M., J.A.G.A., J.G.-T., J.B.-L., J.M.-P., M.D.-S., P.C., L.T.-F., H.A.-N., E.G.-A. and F.J.J.-J.; Methodology, E.G.-M., J.A.G.A., J.G.-T., H.A.-N. and F.J.J.-J.; Project administration, E.G.-M., J.A.G.A. and F.J.J.-J.; Resources, E.G.-M., J.A.G.A., H.A.-N. and F.J.J.-J.; Software, E.G.-M. and J.A.G.A.; Supervision, E.G.-M., J.A.G.A., H.A.-N. and F.J.J.-J.; Validation, E.G.-M., J.A.G.A. and F.J.J.-J.; Visualization, E.G.-M., J.A.G.A. and F.J.J.-J.; Writing—original draft, E.G.-M., J.A.G.A., H.A.-N. and F.J.J.-J.; Writing—review and editing, E.G.-M., J.A.G.A., J.B.-L., H.A.-N. and F.J.J.-J. All authors have read and agreed to the published version of the manuscript.

Funding

The work in the authors’ laboratory is supported in part by Grants PI24/01358 and PI21/01683 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Madrid, Spain, as well as GR24126 from Junta de Extremadura, Merida, Spain. The publication has been co-funded at 85% by the European Union, the European Regional Development Fund, and the Regional Government of Extremadura. Managing Authority. Spanish Ministry of Finance, GR24126.

Institutional Review Board Statement

The study was conducted in accordance with the ethical principles established by the Declaration of Helsinki (1975) and received approval from the respective Clinical Research Ethics Committees of the University Hospital “Príncipe de Asturias” (University of Alcalá, Alcalá de Henares, Madrid, Spain; approval code PI02/2005, 27 April 2005) and the University Hospital of Badajoz (Badajoz, Spain no approval code; 1 April 2004).

Data Availability Statement

All data relating to the current study, intended for reasonable use, are available from J.A.G. Agúndez (University Institute of Molecular Pathology Biomarkers, University of Extremadura, Cáceres, Spain) and Hortensia Alonso-Navarro and F.J. Jiménez-Jiménez (Section of Neurology, Hospital del Sureste, Arganda del Rey, Madrid, Spain).

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Patsopoulos, N.A.; De Jager, P.-L. Genetic and Gene Expression Signatures in Multiple Sclerosis. Mult. Scler. 2020, 26, 576–581. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Kim, W.; Patsopoulos, N.A. Genetics and Functional Genomics of Multiple Sclerosis. Semin. Immunopathol. 2022, 44, 63–79. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Mechelli, R.; Umeton, R.; Manfrè, G.; Romano, S.; Buscarinu, M.C.; Rinaldi, V.; Bellucci, G.; Bigi, R.; Ferraldeschi, M.; Salvetti, M.; et al. Reworking GWAS Data to Understand the Role of Nongenetic Factors in MS Etiopathogenesis. Genes 2020, 11, 97. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Zarghami, A.; Li, Y.; Claflin, S.B.; van der Mei, I.; Taylor, B.V. Role of Environmental Factors in Multiple Sclerosis. Expert Rev. Neurother. 2021, 21, 1389–1408. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Waubant, E.; Lucas, R.; Mowry, E.; Graves, J.; Olsson, T.; Alfredsson, L.; Langer-Gould, A. Environmental and Genetic Risk Factors for MS: An Integrated Review. Ann. Clin. Transl. Neurol. 2019, 6, 1905–1922. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. McGarry, T.; Biniecka, M.; Veale, D.-J.; Fearon, U. Hypoxia, Oxidative Stress and Inflammation. Free Radic. Biol. Med. 2018, 125, 15–24. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Gambini, J.; Stromsnes, K. Oxidative Stress and Inflammation: From Mechanisms to Therapeutic Approaches. Biomedicines 2022, 10, 753. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Ramos-González, E.J.; Bitzer-Quintero, O.K.; Ortiz, G.; Hernández-Cruz, J.J.; Ramírez-Jirano, L.J. Relationship between Inflammation and Oxidative Stress and Its Effect on Multiple Sclerosis. Neurologia 2024, 39, 292–301. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Ibitoye, R.; Kemp, K.; Rice, C.; Hares, K.; Scolding, N.; Wilkins, A. Oxidative Stress-Related Biomarkers in Multiple Sclerosis: A Review. Biomark. Med. 2016, 10, 889–902. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  10. Hollen, C.; Neilson, L.E.; Barajas, R.F., Jr.; Greenhouse, I.; Spain, R.I. Oxidative Stress in Multiple Sclerosis—Emerging Imaging Techniques. Front. Neurol. 2023, 13, 1025659. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Sanabria-Castro, A.; Alape-Girón, A.; Flores-Díaz, M.; Echeverri-McCandless, A.; Parajeles-Vindas, A. Oxidative Stress Involvement in the Molecular Pathogenesis and Progression of Multiple Sclerosis: A Literature Review. Rev. Neurosci. 2024, 35, 355–371. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Jiménez-Jiménez, F.J.; Alonso-Navarro, H.; Salgado-Cámara, P.; García-Martín, E.; Agúndez, J.A.G. Oxidative Stress Markers in Multiple Sclerosis. Int. J. Mol. Sci. 2024, 25, 6289. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Kemp, K.; Redondo, J.; Hares, K.; Rice, C.; Scolding, N.; Wilkins, A. Oxidative Injury in Multiple Sclerosis Cerebellar Grey Matter. Brain Res. 2016, 1642, 452–460. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. van Horssen, J.; Schreibelt, G.; Drexhage, J.; Hazes, T.; Dijkstra, C.D.; van der Valk, P.; de Vries, H.E. Severe Oxidative Damage in Multiple Sclerosis Lesions Coincides with Enhanced Antioxidant Enzyme Expression. Free Radic. Biol. Med. 2008, 45, 1729–1737. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Ljubisavljevic, S.; Stojanovic, I.; Cvetkovic, T.; Vojinovic, S.; Stojanov, D.; Stojanovic, D.; Stefanovic, N.; Pavlovic, D. Erythrocytes’ Antioxidative Capacity as a Potential Marker of Oxidative Stress Intensity in Neuroinflammation. J. Neurol. Sci. 2014, 337, 8–13. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Zagórski, T.; Dudek, I.; Berkan, L.; Mazurek, M.; Kedziora, J.; Chmielewski, H. Aktywność dysmutazy ponadtlenowej (SOD-1) w erytrocytach chorych na stwardnienie rozsiane [Superoxide Dismutase (SOD-1) Activity in Erythrocytes of Patients with Multiple Sclerosis]. Neurol. Neurochir. Pol. 1991, 25, 725–730. [Google Scholar] [PubMed]
  17. Emamgholipour, S.; Hossein-Nezhad, A.; Sahraian, M.A.; Askarisadr, F.; Ansari, M. Evidence for Possible Role of Melatonin in Reducing Oxidative Stress in Multiple Sclerosis through Its Effect on SIRT1 and Antioxidant Enzymes. Life Sci. 2016, 145, 34–41. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Adamczyk-Sowa, M.; Pierzchała, K.; Sowa, P.; Polaniak, R.; Kukla, M.; Hartel, M. Influence of Melatonin Supplementation on Serum Antioxidative Properties and Impact of the Quality of Life in Multiple Sclerosis Patients. J. Physiol. Pharmacol. 2014, 65, 543–550. [Google Scholar] [PubMed]
  19. Naseri, A.; Forghani, N.; Sadigh-Eteghad, S.; Shanehbandi, D.; Asadi, M.; Nasiri, E.; Talebi, M. Circulatory Antioxidant and Oxidative Stress Markers Are in Correlation with Demographics but Not Cognitive Functions in Multiple Sclerosis Patients. Mult. Scler. Relat. Disord. 2022, 57, 103432. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. Bizoń, A.; Chojdak-Łukasiewicz, J.; Kołtuniuk, A.; Budrewicz, S.; Pokryszko-Dragan, A.; Piwowar, A. Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies. Antioxidants 2022, 11, 2416. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Tavazzi, B.; Batocchi, A.P.; Amorini, A.M.; Nociti, V.; D’Urso, S.; Longo, S.; Gullotta, S.; Picardi, M.; Lazzarino, G. Serum Metabolic Profile in Multiple Sclerosis Patients. Mult. Scler. Int. 2011, 2011, 167156. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Obradovic, D.; Andjelic, T.; Ninkovic, M.; Dejanovic, B.; Kotur-Stevuljevic, J. Superoxide Dismutase (SOD), Advanced Oxidation Protein Products (AOPP), and Disease-Modifying Treatment Are Related to Better Relapse Recovery after Corticosteroid Treatment in Multiple Sclerosis. Neurol. Sci. 2021, 42, 3241–3247. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Tasset, I.; Agüera, E.; Sánchez-López, F.; Feijóo, M.; Giraldo, A.I.; Cruz, A.H.; Gascón, F.; Túnez, I. Peripheral Oxidative Stress in Relapsing-Remitting Multiple Sclerosis. Clin. Biochem. 2012, 45, 440–444. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Smirnova, L.P.; Mednova, I.A.; Krotenko, N.M.; Alifirova, V.M.; Ivanova, S.A. IgG-Dependent Dismutation of Superoxide in Patients with Different Types of Multiple Sclerosis and Healthy Subjects. Oxidative Med. Cell. Longev. 2020, 2020, 8171020. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Polachini, C.R.; Spanevello, R.M.; Zanini, D.; Baldissarelli, J.; Pereira, L.B.; Schetinger, M.R.; da Cruz, I.B.; Assmann, C.E.; Bagatini, M.D.; Morsch, V.M. Evaluation of Delta-Aminolevulinic Dehydratase Activity, Oxidative Stress Biomarkers, and Vitamin D Levels in Patients with Multiple Sclerosis. Neurotox. Res. 2016, 29, 230–242. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Ozben, S.; Kucuksayan, E.; Koseoglu, M.; Erel, O.; Neselioglu, S.; Ozben, T. Plasma Thiol/Disulphide Homeostasis Changes in Patients with Relapsing-Remitting Multiple Sclerosis. Int. J. Clin. Pract. 2021, 75, e14241. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Pădureanu, R.; Albu, C.V.; Pădureanu, V.; Bugă, A.M. Oxidative Stress and Vitamin D as Predictors in Multiple Sclerosis. Curr. Health Sci. J. 2020, 46, 371–378. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Syburra, C.; Passi, S. Oxidative Stress in Patients with Multiple Sclerosis. Ukr. Biokhim. Zh. 1999, 71, 112–115. [Google Scholar]
  29. Wigner, P.; Dziedzic, A.; Synowiec, E.; Miller, E.; Bijak, M.; Saluk-Bijak, J. Variation of genes encoding nitric oxide synthases and antioxidant enzymes as potential risks of multiple sclerosis development: A preliminary study. Sci. Rep. 2022, 12, 10603. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Siokas, V.; Raptis, A.E.P.; Karagiorgou, L.; Katsarou, M.-S.; Liampas, I.; Marogianni, C.; Tsolakou, A.; Tsatsakis, A.; Drakoulis, N.; Dardiotis, E.; et al. Investigation of genetic variants in antioxidant enzymes (SOD2 rs4880, CAT rs1001179) and their association with clinical phenotypes of multiple sclerosis: A case–control study. Acta Neurol. Scand. 2025, 2025, 3853574. [Google Scholar] [CrossRef] [Scilit]
  31. McDonald, W.I.; Compston, A.; Edan, G.; Goodkin, D.; Hartung, H.P.; Lublin, F.D.; McFarland, H.F.; Paty, D.W.; Polman, C.H.; Reingold, S.C.; et al. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 2001, 50, 121–127. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.R.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.I.W.; Daly, M.J.; et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81, 559–575. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Benjamini, Y.; Drai, D.; Elmer, G.; Kafkafi, N.; Golani, I. Controlling the False Discovery Rate in Behavior Genetics Research. Behav. Brain Res. 2001, 125, 279–284. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Capurso, C.; Solfrizzi, V.; D’Introno, A.; Colacicco, A.M.; Capurso, S.A.; Bifaro, L.; Menga, R.; Santamato, A.; Seripa, D.; Pilotto, A.; et al. Short arm of chromosome 11 and sporadic Alzheimer’s disease: Catalase and cathepsin D gene polymorphisms. Neurosci. Lett. 2008, 432, 237–242. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Vogrinc, D.; Gregorič Kramberger, M.; Emeršič, A.; Čučnik, S.; Goričar, K.; Dolžan, V. Genetic Polymorphisms in Oxidative Stress and Inflammatory Pathways as Potential Biomarkers in Alzheimer’s Disease and Dementia. Antioxidants 2023, 12, 316. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Ravnik-Glavač, M.; Goričar, K.; Vogrinc, D.; Koritnik, B.; Lavrenčič, J.G.; Glavač, D.; Dolžan, V. Genetic Variability of Inflammation and Oxidative Stress Genes Affects Onset, Progression of the Disease and Survival of Patients with Amyotrophic Lateral Sclerosis. Genes 2022, 13, 757. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Barbo, M.; Koritnik, B.; Leonardis, L.; Blagus, T.; Dolžan, V.; Ravnik-Glavač, M. Genetic Variability in Oxidative Stress, Inflammatory, and Neurodevelopmental Pathways: Impact on the Susceptibility and Course of Spinal Muscular Atrophy. Cell. Mol. Neurobiol. 2024, 44, 71. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  38. Redenšek, S.; Flisar, D.; Kojović, M.; Gregorič Kramberger, M.; Georgiev, D.; Pirtošek, Z.; Trošt, M.; Dolžan, V. Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease. J. Neuroinflamm. 2019, 16, 50. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  39. Redenšek, S.; Jenko Bizjan, B.; Trošt, M.; Dolžan, V. Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson’s Disease. Front. Genet. 2019, 10, 461. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Wiener, H.W.; Perry, R.T.; Chen, Z.; Harrell, L.E.; Go, R.C.P. A polymorphism in SOD2 is associated with development of Alzheimer’s disease. Genes Brain Behav. 2007, 6, 770–775. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  41. Gamarra, D.; Elcoroaristizabal, X.; Fernández-Martínez, M.; de Pancorbo, M.M. Association of the C47T Polymorphism in SOD2 with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease in Carriers of the APOEε4 Allele. Dis. Markers 2015, 2015, 746329. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Siokas, V.; Stamati, P.; Pateraki, G.; Liampas, I.; Aloizou, A.M.; Tsirelis, D.; Nousia, A.; Sgantzos, M.; Nasios, G.; Bogdanos, D.P.; et al. Analysis of SOD2 rs4880 Genetic Variant in Patients with Alzheimer’s Disease. Curr. Issues Mol. Biol. 2022, 44, 4406–4414. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Yu, W.J.; Li, N.N.; Tan, E.K.; Cheng, L.; Zhang, J.H.; Mao, X.Y.; Chang, X.L.; Zhao, D.M.; Liao, Q.; Peng, R. No association of four candidate genetic variants in MnSOD and SYNIII with Parkinson’s disease in two Chinese populations. PLoS ONE 2014, 9, e88050. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Liu, C.; Fang, J.; Liu, W. Superoxide dismutase coding of gene polymorphisms associated with susceptibility to Parkinson’s disease. J. Integr. Neurosci. 2019, 18, 299–303. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  45. Wu, Y.R.; Chang, K.H.; Chao, C.Y.; Lin, C.H.; Chen, Y.C.; Liu, T.W.; Lee-Chen, G.J.; Chen, C.M. Association of SOD2 p.V16A polymorphism with Parkinson’s disease: A meta-analysis in Han Chinese. J. Formos. Med. Assoc. 2021, 120, 501–507. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
The Antigen-Presentation Bottleneck in Pediatric Solid Tumors: Developmental Antigens, MHC-I Suppression, and Therapeutic Restoration of Tumor Immune Recognition
Previous
Metabolic Engineering of Yarrowia lipolytica for De Novo Biosynthesis of Umbelliferone
Next